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Neuromyelitis optica spectrum disorders
Comparison according to the phenotype and serostatus
ABSTRACT
Objective: To (1) determine the value of the recently proposed criteria of neuromyelitis optica
(NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms
(NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the
clinical significance of the serologic status in patients with NMO.
Methods: This was a retrospective, multicenter study of 181 patients fulfilling the 2006
NMO criteria (n 5 127) or NMO/LF criteria with AQP4-IgG (n 5 54). AQP4-IgG and myelin
oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using
cell-based assays.
Results: Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39
years (range 10–77). Compared to patients with NMO and AQP4-IgG (n 5 94), those with NMO/
LF presentedmore often with longitudinally extensive transverse myelitis (LETM) (p,0.001), and
had lower relapse rates (p5 0.015), but similar disability outcomes. Nonwhite ethnicity and optic
neuritis presentation doubled the risk for developing NMO compared with white race (p 5 0.008)
or LETM presentation (p5 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval
[CI] 1.4–13.6) and older age at onset were associated with worse outcome (for every 10-year
increase, HR 1.7, 95% CI 1.3–2.2). Patients with NMO and MOG-IgG (n 5 9) had lower female:
male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-
seronegative patients (p , 0.001).
Conclusions: In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype
support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with
worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical
outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic
and serologic classification is useful. Neurol Neuroimmunol Neuroinflamm 2016;3:e225; doi:
10.1212/NXI.0000000000000225
GLOSSARY
AQP4-IgG 5 aquaporin-4 immunoglobulin G; ARR 5 annualized relapse rate; CBA 5 cell-based assay; CI 5 confidence
interval; EDSS5 Expanded Disability Status Scale; HR5 hazard ratio; IQR5 interquartile range; LF5 limited forms;MOG5
myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis optica
spectrum disorders; OR 5 odds ratio.
Neuromyelitis optica (NMO) is an inflammatory CNS disorder that preferentially affects the
optic nerve and spinal cord. The discovery of aquaporin-4 immunoglobulin G (AQP4-IgG)
antibodies as a specific biomarker of NMO led in 2006 to the development of revised
NMO diagnostic criteria that required both optic neuritis and myelitis and AQP4-IgG
seropositivity as supportive criteria.1 In 2007, the term NMO spectrum disorders (NMOSD)
was introduced to include AQP4-IgG-seropositive patients with limited or inaugural forms
(e.g., recurrent optic neuritis or longitudinally extensive transverse myelitis [LETM]), or with
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manifestations outside of the optic nerve
and spinal cord (e.g., hiccups or nausea and
vomiting).2
In 2015, an International Panel proposed
new diagnostic criteria that unify patients with
typical NMO and the more recently defined
NMOSD under the term NMOSD.3 These
criteria are based on the presence or absence
of AQP4-IgG and on the assumption that pa-
tients with limited forms (NMO/LF) will
develop typical NMO over time.2,3 However,
in some patients the interval between the
disease-defining events of optic neuritis and
myelitis and conversion to NMOmay be years
or decades.2,4,5 Why some patients remain
with limited forms for prolonged periods of
time and if having a limited form impacts dis-
ability outcomes are unknown. Both the 2006
and the 2015 criteria allow the diagnosis of
NMO or NMOSD, respectively, in patients
without AQP4-IgG.6,7 Recent studies have
shown that some of these patients have anti-
bodies to myelin oligodendrocyte glycoprotein
(MOG).7–9 Moreover, studies suggest that the
clinical outcome of patients with NMO and
MOG-IgG is different from that of patients
with NMO with AQP4-IgG or who are dou-
ble seronegative.7,9
These questions are important because in
the newly proposed criteria different clinical
phenotypes such as NMO or NMO/LF are
no longer considered. To address this, we ana-
lyzed the demographic and clinical features of
a Spanish cohort of patients with NMOSD
with AQP4-IgG who had either the NMO
phenotype (2006 criteria) or NMO/LF to
identify predictors of conversion to NMO
and impact on disability outcomes. We also
reviewed the clinical outcomes of patients with
the NMO phenotype according to the pres-
ence or absence of AQP4-IgG or MOG-IgG.
METHODS Case selection and data collection. Clinical
information and samples for this observational, retrospective,
multicenter study were collected from 59 centers through the
multiple sclerosis (MS) study group of the Spanish Society of
Neurology and the Spanish MS Network (Red Española de Escle-
rosis Múltiple) from January 2013 to January 2015. Overall, 181
patients who at last follow-up fulfilled the 2006 NMO criteria
(n5 127) or had NMO/LF associated with AQP4-IgG (n5 54)
were included.1,2 Epidemiologic data, including demographic,
clinical, CSF (cell count, protein levels, and oligoclonal bands),
MRI findings (brain MRI classified as normal and abnormal with
or without the Paty or Barkhof criteria,10 and number and
extension of spinal cord lesions), treatment, and outcome, were
obtained from medical records and information collected from
referring neurologists through a structured questionnaire
designed for NMO. All serum samples were tested for AQP4-
IgG by immunohistochemistry and an in-house cell-based assay
(CBA) with live HEK293 cells transfected with the aquaporin-4-
M23 isoform as reported.9,11 All but 5 samples from AQP4-IgG-
seropositive and 4 seronegative cases were tested for MOG-IgG
using an in-house CBA with HEK293 cells transfected with the
full-length MOG C-terminally fused to EGFP.9 The outcome
reached at last follow-up was evaluated by the Expanded
Disability Status Scale (EDSS) score.12 Severe visual disability
was defined as sustained visual acuity #20/100 with best
correction possible during at least 6 months after an optic
neuritis attack.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Ethics Committee of
the Hospital Clinic, and written consent was obtained for all par-
ticipants. Samples were deposited in a registered biobank of the
Institut dInvestigació Biomèdica August Pi i Sunyer (IDIBAPS),
Barcelona, Spain.
Statistical methods. Characteristics were compared between
patient groups using x2 (or Fisher exact) tests for categorical data
and Student t test (or Wilcoxon rank sum) for continuous data.
The Kaplan-Meier method was used to estimate the time to first
and second recurrence, conversion to NMO phenotype, onset of
chronic therapy, and to reach EDSS scores of 6 and 8. Survival
curves were compared using log-rank tests and predictive factors
for disability were assessed with Cox proportional hazards
regression models. Disease characteristics along the disease
course were compared using regression models with generalized
estimating equations, logistic regression for binary data, and
linear regression for continuous data, and adjusted by the
follow-up time for each patient. Age, sex, ethnicity, type of
syndrome at onset, and severity after the first event were
included as predictive factors for conversion, and annualized
relapse rate was added as predictive factor for disability.
Chronic therapy was included as a time-dependent covariable
in both analyses. Two-sided p values ,0.05 were considered
statistically significant. Analyses were performed using SPSS
version 19.0.
RESULTS Demographic, clinical, and serologic
characteristics of the cohort. Clinical and demo-
graphic data of the 181 patients are summarized in
table 1. The median age at disease onset was 39 years
(range 10–77 years) and the disease duration 6.4 years
(0.2–50 years). Patients were mainly white (86%),
with a female:male ratio of 6.5:1. The frequency of
optic neuritis or transverse myelitis presentation at
onset was similar (38% and 40%, respectively);
simultaneous or sequential (,1 month from onset)
optic and spinal attacks were infrequent (14%). The
clinical phenotype and disease course at the last follow-
up is detailed in figure e-1 at Neurology.org/nn. All
but 20 patients (11%) had a relapsing course, and 150
(83%) were on chronic therapy. In total, 148 patients
(82%) had AQP4-IgG, 9 (5%) MOG-IgG, 2 (1%)
both, and 22 (13%) were double seronegative. The
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2 patients with both antibodies were excluded from the
analyses of clinical-immunologic correlates.
Demographic and clinical differences between AQP4-
IgG-positive NMO patients and those who remained
with NMO/LF. Examining the entire cohort of 148
AQP4-IgG patients showed those with NMO/LF
presented more frequently with LETM at first (p ,
0.001) and second attack (p5 0.003) than those with
NMO (table 2). The age at disease onset of the patients
who presented with LETM and remained as NMO/LF
was older than those who developed the NMO
phenotype (median 47 vs 34 years, p , 0.001).
We investigated which variables predicted conver-
sion to NMO in this cohort. We found that non-
white ethnicity doubled the risk as compared with
white race (hazard ratio [HR] 2.2, 95% confidence
interval [CI], 1.2–3.9, p 5 0.008); optic neuritis
increased the risk 2-fold as compared with LETM
presentation (HR 2.2, 95% CI 1.2–3.9, p 5 0.008)
and almost 4-fold as compared with brainstem attack
(HR 3.9, 95% CI 1.2–13.0, p 5 0.024). Age at dis-
ease onset only influenced the risk for developing
NMO in those who presented with LETM, being
lower for older patients (30–40 years, HR 0.19,
95% CI 0.07–0.55; $50 years HR 0.054, 95% CI
0.01–0.27; compared with ,30 years, p , 0.0001).
The 5-year conversion risk to NMO was 63.2%
(95% CI 48%–78%) for optic neuritis, 41.4%
(95% CI 26%–57%) for LETM, and 23% (95%
CI 1%–46%) for brainstem syndrome (figure 1A).
Regarding disease severity, the mean annualized
relapse rate (ARR) for the patients who remained with
NMO/LF was significantly lower (table 2); the mean
number of relapses remained lower after adjusting for
time of follow-up (3 vs 4.8, p 5 0.018). NMO/LF
patients who remained monophasic had significantly
shorter disease duration than those who relapsed
(median 2 vs 5.5 years, p , 0.001). Patients with
NMO/LF were treated earlier than those with
NMO (median time from disease onset to therapy
initiation 6.3 months [interquartile range (IQR)
3.7–18.6 months] vs 17.7 months [IQR 5.6–60
months], p 5 0.014), and had a better response;
the mean (SD) ARR after treatment decreased to
0.3 (0.6) in NMO/LF and 0.7 (0.8) in NMO pa-
tients, p 5 0.035. Seventy of the 84 patients (83%)
who received chronic therapy were treated after ful-
fillment of NMO criteria (e-Results).
The EDSS score at last follow-up was significantly
lower in those who remained NMO/LF than in pa-
tients with NMO (table 2), but the difference was
due to the lower EDSS score of the patients who re-
mained as optic neuritis (median 2.0, range 1.0–4.0)
or brainstem syndrome (median 1.0, range 0–2.0).
When we compared the motor disability of patients
with NMO with that of patients who remained with
LETM, no significant differences were found in the
proportion of patients who reached severe disability
(EDSS score of 6.0). There was also no difference in
the percentage of patients with severe visual disability
(visual acuity #20/100) when comparing patients
with NMO with those who remained with optic neu-
ritis (table 2). The same results were found after adjust-
ing for time of follow-up (motor disability: odds ratio
[OR] 0.69, 95% CI 0.3–1.6, p 5 0.385; visual disa-
bility: OR 1.027, 95% CI 0.29–3.65, p 5 0.970).
Predictors for disability in patients with AQP4-IgG. In
the analyses for the development of disability, we
found that nonwhite ethnicity (HR 4.3, 95% CI
1.4–13.6, p , 0.012), older age at disease onset
(HR 1.7 for every 10-year increase in age at onset;
95% CI 1.3–2.2, p, 0.0001) (figure 1B), and higher
residual disability after first attack increased the risk of
requiring a cane to walk (EDSS 6.0) (HR 1.3, 95%
CI 1.1–1.6, p 5 0.017). In the analysis for visual
outcome, older age at disease onset (OR 1.9 for
every 10-year increase in age at onset; 95% CI 1.2–
2.9, p5 0.005), higher disability after the first attack
Table 1 Demographic and disease characteristics of the cohort
Values (total n 5 181)
Sex, female:male 157:24 (ratio 6.5:1)
White ethnicity, n (%) 155 (86)
Age at onset, y, median (range) 39 (10–77)
Coexisting autoimmune disease, n (%) 40 (22)
Onset attack type, n (%)
Optic neuritis 69 (38)
Myelitis 73 (40)
Simultaneousa optic neuritis 1 myelitis 26 (14)
Brainstem/brain 13 (7)
Follow-up duration, y, median (range) 6.4 (0.2–50)
Time to first relapse, mo, median (95% CI) 13 (9–16)
Annualized relapse rate, mean 6 SD 1.0 6 1.3
Disabilityb,c
Outcome reached at last follow-up
Last EDSS score, median (range) 3.5 (0–9.0)
EDSS score ‡6.0, n (%) 60 (36)
EDSS score ‡8.0, n (%) 24 (15)
Visual acuity £20/100, n (%) 59 (42)
Patients who died, n (%) 9 (5)
Abbreviations: CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale.
a Simultaneous or sequential (less than 1 month from symptom onset) optic and spinal
attack.
b For the EDSS outcome comparison (EDSS at last follow-up $6.0 and $8.0), only those
patients who had at least one myelitis attack were considered (n 5 165).
c For the visual outcome comparison (visual acuity at last follow-up #20/100), only those
patients who had at least one optic neuritis attack were considered (n 5 140).
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(OR 1.7, 95% CI 1.1–2.6, p 5 0.015), and time of
follow-up (by year, OR 1.2, 95% CI 1.1–1.3, p 5
0.028) were associated with worse visual outcome.
No significant effect was observed in association
with ethnicity, initial syndrome, ARR, or chronic
therapy.
Demographic and clinical differences among patients
with NMO phenotype according to antibody status.
Patients with NMO and AQP4-IgG had a
significantly higher female:male ratio (14.7:1) than
patients who were double seronegative (1.4:1) or
with MOG-IgG (0.8:1), p , 0.001 (table 3; table
e-1). At last follow-up, patients with MOG-IgG
had a lower median EDSS score (1.0, range 0–3.0)
than those with AQP4-IgG (4.5, range 1.0–9.0) and
those who were double seronegative (5.0, range
0–9.0), p , 0.001 (table 3). Due to the small
sample size and the fact that none of the patients
with MOG-IgG reached the EDSS score of 6.0, only
a trend to lower risk of motor disability was observed in
comparison with AQP4-IgG and double seronegative
patients (log-rank test, p 5 0.089) (figure 1C). There
were no differences among the 3 groups in severity of
disease at onset, time to first relapse, ARR, and
frequency of relapses within 1 or 2 years of onset
(table 3). The median delay to start therapy was not
significantly different among the groups (around 0.5–
1.5 years), and the comparative analyses of the effect of
Table 2 Demographic and clinical features and outcome of AQP4-IgG-positive patients with NMO or NMO/LF
NMO (n 5 94)a NMO/LF (n 5 54) p Value
Sex, female:male 88:6 (ratio 14.7:1) 50:4 (ratio 12.5:1) 0.811
White ethnicity, n (%) 76 (81) 47 (87) 0.855
Age at onset, y, median (range) 37 (11–77) 43 (10–74) 0.054
Onset attack type, n (%)
Optic neuritis 49 (52) 11 (20)
Myelitis 28 (30) 33 (61) ,0.001b
Simultaneousc optic neuritis 1 myelitis 14 (15) 0
Brainstem/brain 3 (3) 10 (19)
EDSS score after first attack, median (range) 3.0 (0–8.0) 3.3 (0–7.0) 0.315
Monophasic course,d n (%) 2 (2) 11 (20) ,0.001b
Chronic treatment, n (%) 84 (89) 40 (74) 0.015b
Follow-up, y, median (range) 7.2 (0.2–50) 5.0 (0.7–37) 0.005b
Annualized relapse rate, mean 6 SD 1.2 6 1.6 0.7 6 0.5 0.015b
Estimated % patients with relapses
Within 1 y of onset 54 41 0.076
Within 2 y of onset 67 53 0.076
Time to first relapse, mo, median (95% CI) 12 (9–15) 22 (10–34) 0.076
Disabilitye,f
Outcome reached at last follow-up
Last EDSS score, median (range) 4.5 (1.0–9.0) 2.5 (0–8.0) ,0.001b
EDSS score ‡6.0, n (%) 38 (40) 14 (37) 1.00
EDSS score ‡8.0, n (%) 15 (16) 3 (8) 0.396
Visual acuity £20/100, n (%) 41 (44) 6 (46) 1.00
Patients who died, n (%) 7 (7.5) 1 (1.9) 0.147
Abbreviations: AQP4-IgG 5 aquaporin-4 immunoglobulin G; CI 5 confidence interval; EDSS 5 Expanded Disability Status
Scale; LF 5 limited forms; NMO 5 neuromyelitis optica.
a Two patients with NMO with both AQP4-IgG and antibodies to myelin oligodendrocyte glycoprotein presented with a
simultaneous optic and spinal attack and were excluded from the analyses.
bSignificant.
c Simultaneous or sequential (less than 1 month from symptom onset) optic and spinal attack.
dMonophasic course: patients without relapses after their initial attack.
e For the EDSS outcome comparison (EDSS at last follow-up$6.0 and$8.0), only those patients who remained as NMO/LF
and who had at least one myelitis attack were considered (n 5 38).
f For the visual outcome comparison (visual acuity at last follow-up # 20/100), only those patients who remained as NMO/
LF and who had at least one optic neuritis attack were considered (n 5 13).
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therapy on relapse rate did not reveal significant
differences; after therapy, the mean (SD) ARR for
AQP4-IgG patients decreased from 3.6 (5.5) to 0.7
(0.8), for double seronegative from 3.2 (3.7) to 0.6
(1.1), and for MOG-IgG from 5.2 (3.9) to 0.1 (0.2)
(p 5 0.400) (e-Results).
DISCUSSION This study of a large cohort of NMO
patients identified by uniform criteria and sensitive
assays for AQP4-IgG and MOG-IgG detection
provides several important observations: (1) the
median time of conversion to NMO in patients
with AQP4-IgG who develop the NMO phenotype
is 1 year; however, there is a subgroup of patients
with AQP4-IgG who do not convert to NMO after
a median follow-up of 5 years; (2) presentation with
optic neuritis and nonwhite ethnicity are predictors
of NMO conversion; (3) the final motor or visual
disability outcome of patients with AQP4-IgG who
do and do not convert to NMO is the same; (4)
older age and nonwhite ethnicity are predictors of
worse disability outcome irrespective of syndrome;
(5) patients with NMO and AQP4-IgG and those
who are double seronegative have similar clinical
profiles in terms of relapses and disability; and (6)
patients with NMO and MOG-IgG have better
outcomes compared to patients with NMO and
AQP4-IgG or who are double seronegative.
The 2015 proposed diagnostic criteria unifying
the traditional NMO and modern NMOSD defini-
tions for patients with AQP4-IgG was predicated
on an absence of differences in clinical behavior, im-
munopathogenesis, and treatment of these patients.3
Our results support this aspect of the criteria as we
found that all AQP4-IgG-seropositive patients have
similar motor or visual disability outcomes.
We observed that presentation as optic neuritis
increased the risk of developing NMO compared with
presentation as LETM, but this was only significant
for those patients with LETM aged $30 years. The
higher risk of developing NMO in patients who pre-
sent with optic neuritis was also observed in a previ-
ous study of patients with AQP4-IgG-seropositive
NMOSD, although the influence of age was not
noticed.5 Similarly, these authors also found a greater
likelihood of developing NMO in Afro-Caribbean
Figure 1 Kaplan-Meier estimation of time to
neuromyelitis optica (NMO) conversion
and development of motor disability
(A) Months from onset to develop NMO according to the
onset attack type: patients with optic neuritis, and those
with longitudinally extensive transverse myelitis (LETM)
aged,30 years, converted earlier than patients with LETM
aged.30 years or with brainstem syndrome (p,0.001). (B)
Months from onset to use a cane (Expanded Disability Sta-
tus Scale [EDSS] score 6.0) by age at disease onset: older
patients were significantly more likely than younger pa-
tients to develop motor disability over time (p , 0.001).
(C) Years from onset to use a cane by antibody status in
NMO patients: at 5 years after onset, 26% of aquaporin-
4 immunoglobulin G (AQP4-IgG)–positive patients, 19% of
double-seronegative patients, and none of the myelin oligo-
dendrocyte glycoprotein (MOG)–IgG-positive patients were
expected to need a cane to walk (EDSS score 6.0) (p 5
0.089). EDSS score 6.0 5 intermittent or unilateral assis-
tance required to walk 100 meters with or without resting.
ON 5 optic neuritis.
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patients than Caucasians,5 supporting a contribution
of genetic factors to the course of the disease.
Our results confirm previous observations that pa-
tients with AQP4-IgG who remain as NMO/LF present
more frequently with LETM and are older than those
who convert to NMO.5,13,14 The cause of the lower risk
for patients with LETM to develop NMO is not clear.
In our cohort of AQP4-IgG-positive patients, those with
LETM were treated earlier than those with optic neuri-
tis, and immunotherapy could have prevented the
development of NMO.However, early treatment would
not explain the differences observed between younger
(,30 years) and older ($50 years) patients with LETM.
Moreover, in patients with NMO/LF, the time to ther-
apy initiation was not significantly different between
patients who presented with optic neuritis or LETM.
There is widespread acceptance that attack preven-
tion with immunosuppressant therapies is effective in
reducing NMO relapses, and our study confirms a
significant reduction in the relapse rate in both







(n 5 9)a p Value
Sex, female:male 88:6 (ratio 14.7:1) 13:9 (ratio 1.4:1) 4:5 (ratio 0.8:1) ,0.001b
White ethnicity, n (%) 76 (81) 21 (96) 9 (100) 0.773
Age at onset, y, median (range) 37 (11–77) 32 (10–57) 35 (17–51) 0.315
Coexisting autoimmune diseases, n (%) 18 (19) 7 (32) 1 (11) 0.318
Onset attack type, n (%)
Optic neuritis 49 (52) 7 (32) 2 (22)
Myelitis 28 (30) 9 (41) 3 (33) 0.166
Simultaneousc optic neuritis 1 myelitis 14 (15) 6 (27) 4 (45)
Brainstem/brain 3 (3) 0 0
EDSS score after first attack, median (range) 3.0 (0–8.0) 2.8 (2.0–6.0) 3.5 (0–4.0) 0.681
Monophasic course,d n (%) 2 (2) 3 (14) 2 (22) 0.008b
Chronic treatment, n (%) 84 (89) 18 (82) 6 (67) 0.130
Follow-up, y, median (range) 7.2 (0.2–50) 6.4 (1–36) 3.7 (0.7–36) 0.232
Median time to develop NMO,e mo, interquartile range 12 (3–37) 6.5 (1–18) 6 (1–44) 0.521
No. of relapses, median (range) 4 (1–27) 2 (1–11) 3 (1–7) 0.129
Estimated % patients with relapses
Within 1 y of onset 54 47 56 0.820
Within 2 y of onset 69 66 56 0.820
Time to first relapse, mo, median (95% CI) 12 (9–15) 13 (8–18) 7 (4–11) 0.820
Annualized relapse rate, mean 6 SD 1.2 6 1.6 0.8 6 0.7 1.0 6 0.8 0.800
Outcome reached at last follow-up
Last EDSS score, median (range) 4.5 (1.0–9.0) 5.0 (0–9.0) 1.0 (0–3.0) ,0.001b
EDSS score ‡6.0, n (%) 38 (40) 8 (36) 0 0.053
EDSS score ‡8.0, n (%) 15 (16) 6 (27) 0 0.170
Visual acuity £20/100, % 41 (44) 11 (50) 1 (11) 0.112
Kaplan-Meier estimated % of patients expected
to reach disability outcome at 5 y after onset
EDSS ‡6.0 26 19 0 0.089
EDSS ‡8.0 10 12 0 0.196
Patients who died, n (%) 7 (7.5) 1 (4.5) 0 0.658
Abbreviations: AQP4-IgG 5 aquaporin-4 immunoglobulin G; CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; MOG 5 myelin oligoden-
drocyte glycoprotein; NMO 5 neuromyelitis optica.
a Two patients with NMO with both AQP4-IgG and MOG-IgG presented with a simultaneous optic and spinal attack and were excluded from the analyses.
bSignificant.
c Simultaneous or sequential (less than 1 month from symptom onset) optic and spinal attack.
dMonophasic course: patients without relapses after their initial attack.
e Fulfillment of the 2006 NMO criteria.1
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AQP4-IgG NMO and NMO/LF groups. The fact
that patients with AQP4-IgG NMO/LF who re-
mained monophasic had significantly shorter disease
duration than those who relapsed supports the need
of a follow-up of at least 5 years to qualify as a mon-
ophasic disease course, as suggested by the 2015
criteria.3 The contribution, however, of early thera-
peutic intervention to modulate the natural history of
NMO/LF remains unclear and will only be ascer-
tained with prospective studies in which clinical phe-
notype classification will be relevant. Until these
studies are done, as disability outcome is similar for
patients with AQP4-IgG who do and do not convert
to NMO, as well as for patients who are double sero-
negative, early preventive therapy is warranted in
these patients.
The 2015 criteria allow the diagnosis of NMOSD
in patients without AQP4-IgG.6,7 This is a matter of
debate. Previous studies showed some clinical differ-
ences between AQP4-IgG-positive and -negative pa-
tients,15 including a lower female predominance in
those without AQP4-IgG,4,6 similar to the findings
in the current study (1.4 vs 14.7). The phenotypic
variability between AQP4-IgG-positive and -negative
patients may be partially explained by the presence of
MOG-IgG in a subgroup of the AQP4-IgG-seronegative
patients. In the current study, we identified
MOG-IgG in 29% of patients who would have been
classified as seronegative. Compared to AQP4-IgG-
seropositive or double-seronegative patients, those
with MOG-IgG showed a male predominance, more
often presented with simultaneous or sequential (,1
month from onset) optic and spinal attacks, and more
commonly had a monophasic disease course. Addi-
tionally, these patients had better outcomes even
though the severity of disability during the initial
attack and relapse rates were similar to the AQP4-
IgG-seropositive or double-seronegative patients.
These data and prior studies confirm the distinct
prognosis for patients with MOG-IgG,7,9,16 and sup-
port the importance of testing for MOG-IgG. More-
over, our study confirms that double-positive cases
are very rare. The 2 double-positive patients pre-
sented with simultaneous optic neuritis and LETM,
and had a typical relapsing course. This is in contrast
with a recently reported case that presented with an
acute demyelinating encephalomyelitis and developed
a fulminant clinical course.17
Even with the addition of MOG-IgG testing, 19%
of patients in our study remained seronegative. This
group of patients had similar clinical features and dis-
ability outcome to AQP4-IgG-seropositive patients,
consistent with a recent report of the Mayo Clinic.6
For example, the percentage of AQP4-IgG-seropositive
patients who relapsed within the first (51%) or second
(62%) year after onset, and the estimated median time
to require a cane (15 years), was similar.6 The challenge
will be to determine if the seronegativity of this group
is due to a lack of sensitivity of current antibody assays
or the presence of uncharacterized immune responses.
Additionally, it is likely that this is not a clinically
homogenous group, highlighting the importance of
collecting detailed phenotypic and epidemiologic data.
Our study has limitations related to its retrospec-
tive nature, and the ascertainment bias related to
selection of patients who fulfilled the 2006 and
2007 definitions that were more restrictive than the
recently proposed criteria. However, our findings in
this large cohort of patients support the unified defi-
nition of NMOSD for seropositive AQP4-IgG pa-
tients, and provide novel serologic and clinical
predictors of outcome.
AUTHOR AFFILIATIONS
From the Center of Neuroimmunology (M.S., T.A., N.S.-V., Y.B., P.V.,
F.G., A.S.), Service of Neurology, Hospital Clínic and Institut
dInvestigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de
Barcelona; Neuroimmunology Unit (T.A.), Department of Child Neu-
rology, Sant Joan de Déu Hospital, University of Barcelona, Esplugues
del Llobregat; Servei de Neurologia-Neuroimmunologia (G.A., X.M.),
Centre dEsclerosi Múltiple de Catalunya (CEM-Cat), Vall dHebron
Institut de Recerca, Hospital Universitari Vall dHebron, Universitat
Autònoma de Barcelona; Multiple Sclerosis Unit (J.E.M.-L.), Depart-
ment of Neurology, Hospital Clínico Universitario Virgen de la Arrixaca,
Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM
Universidad Católica San Antonio de Murcia; Department of Neurology
(C.O.-G.), University Hospital San Carlos, IdISSC, Madrid; Department
of Neurology (M.M.), Hospital Universitario de Cruces, Baracaldo;
Department of Neurology (A.A.d.A.), Alava University Hospital, Txagor-
ritxu, Vitoria-Gasteiz; Department of Neurology (Y.A.), University Hos-
pital of Getafe; Department of Neurology (B.C.), Hospital Universitari
La Fe, Valencia; Hospital Universitario de Donostia (J.O.), San Sebas-
tián; Hospital Ruber Internacional (A.J.-H.), Madrid; Clinical Neuro-
immunology and Multiple Sclerosis Unit (M.F.-F.), La Paz University
Hospital, Madrid; Neuroimmunology and Multiple Sclerosis Unit
(L.R.-T.), Department of Neurology, Dr. Josep Trueta University Hos-
pital, IDIBGI, Girona; Multiple Sclerosis Unit (A.C.-C.), Neurology
Department, Hospital Universitari de Bellvitge, LHospitalet de Llobregat;
Neurology Department (M.V.), Reina Sofia Hospital, University of
Cordoba; Department of Neurology (C.d.A.), Hospital General Uni-
versitario Gregorio Marañón, Madrid; Department of Neurology
(V.M.-L.), Hospital Universitario de la Princesa, Madrid; Department
of Neurology (A.C.), Hospital General Universitario de Valencia;
Department of Neurology (C.C.), Hospital Universitari Son Espases,
Palma de Mallorca; Department of Neurology (M.B.R.), Hospital
Universitario Fundación Alcorcón, Madrid; Neurology Department
(C.R.-T.), Hospital Universitario Germans Trias i Pujol, Badalona;
Department of Neurology (A.C.), Hospital Nuestra Señora de
Sonsoles, Avila; Department of Neurology (E.M.), Hospital del
Mar, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques),
Barcelona; and Service of Neurology (A.R.A.), Hospital Universitario
de Basurto, Bilbao, Spain.
AUTHOR CONTRIBUTIONS
Design/conceptualization of the study: M.S., F.G., A.S. Analysis/inter-
pretation of the data, drafting and revising the manuscript: M.S., T.A.,
N.S.-V., Y.B., F.G., A.S. Statistical analysis: M.S., Y.B. Acquisition of
data and revising the manuscript for intellectual content: G.A., J.E.M.-L.,
C.O.-G., M.M., A.A.d.A., Y.A., B.C., J.O., A.J.-H., M.F.-F., L.R.-T.,
A.C.-C., M.V., C.d.A., V.M.-L., A.C., C.C., M.B.R., C.R.-T., A.C.,
E.M., A.R.A., P.V., X.M. All authors have given final approval of the
manuscript.
Neurology: Neuroimmunology & Neuroinflammation 7
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
ACKNOWLEDGMENT
The authors thank Dr. Myrna Rosenfeld for critical review of the manu-
script and Eva Caballero and Mercè Alba for technical assistance.
STUDY FUNDING
This study was supported in part by Red Española de Esclerosis Múltiple
(REEM) Instituto de Salud Carlos III, Spain (RD07/0060/01, P.V.;
RD12/0032/0002, A.S.; Marató de TV3 [20141830], F.G.) and Insti-
tuto de Salud Carlos III, Spain (CM14/00081; T.A.).
DISCLOSURE
M. Sepúlveda reports no disclosures. T. Armangué is an editorial advisory
board member for Pediatria Catalana and receives research support from
Instituto Carlos III (Spain), Asociacion Española de Pediatria, and
Fundacio Marato TV3. N. Sola-Valls reports no disclosures. Georgina
Arrambide has consulted for Biogen-Idec. J.E. Meca-Lallana has con-
sulted for Biogen-Idec, Sanofi-Aventis, and Teva Pharmaceuticals and
received speaker honoraria from Almirall, Merck-Serono, Biogen-Idec,
Sanofi-Aventis, Teva Pharmaceuticals, and Novartis. C. Oreja-Guevara
has consulted for Biogen Idec, Genzyme, Merck-Serono, and Novartis
and received speaker honoraria from Biogen Idec, Genzyme, Merck-
Serono, and Novartis. M. Mendibe, A. Alvarez de Arcaya, and Y. Alandro
report no disclosures. B. Casanova served on the scientific advisory board
for Roche, Biogen-Idec, Genzyme, Teva, Novartis, and Merck-Serono;
has consulted for Roche, Biogen-Idec, Genzyme, Teva, Novartis, and
Merck-Serono; and received research support from Biogen-Idec, Gen-
zyme, and Teva. J. Olascoaga served on the scientific advisory board
for Biogen Idec, Genzyme, Novartis, Roche, and Teva; received travel
funding and/or speaker honoraria from Biogen-Idec, Bayer-Schering,
Genzyme, Merck-Serono, Novartis, and Teva; and received research
support from Biogen Idec, Merck Serono, Novartis, and Teva. A.
Jiménez-Huete and M. Fernández-Fournier report no disclosures. L.
Ramió-Torrentà received travel funding and/or speaker honoraria from
Biogen Idec, Bayer, Merck-Serono, Teva Pharmaceuticals Industries Ltd.,
Novartis, Genzyme, and Almirall. A. Cobo-Calvo, M. Viñals, and C. de
Andrés report no disclosures. V. Meca-Lallana served on the scientific
advisory board for Genzyme and Roche and received travel funding and/
or speaker honoraria from Genzyme, Sanofi-Aventis, Merck-Serono, Teva
Pharmaceuticals Industries Ltd., Novartis, Biogen Idec, and Terumo. A.
Cervelló reports no disclosures. C. Calles received speaker honoraria from
Biogen Idec, Bayer, Merck-Serono, Genzyme, Teva Pharmaceuticals Inc,
and Novartis, and received research support from Biogen Idec, Bayer,
Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd., and No-
vartis. M.B. Rubio, C. Ramo-Tello, and A. Caminero report no disclo-
sures. E. Munteis received speaker honoraria from Biogen Idec, Teva
Pharmaceutical Industries Ltd., Novartis, Almirall, and Genzyme, and
received research support from Biogen and Merck-Serono. A.R.
Antigüedad and Y. Blanco report no disclosures. P. Villoslada served
on the scientific advisory board for Roche, Novartis, Bionure, and Gen-
zyme; received travel funding and/or speaker honoraria from Novartis,
Roche, and Genzyme; is an academic editor for PloSONE; is on the
editorial board for Neurology & Therapy, Curr Treat Options Neurol,
and Multiple Sclerosis and Demyelinating Disorders; holds patents for
methylthioadenosine for the treatment of MS, agnostic neurotrophic
compounds for the treatment of brain diseases, gene signature pattern
as a biomarker for MS, and algorithm for quantifying fractal dimension
in brain MTI; and received research support from Novartis, Roche,
Genzyme, Instituto de Salud Carlos III, European Commission, National
MS Society, Fundación Maraton TV3, Bionure Inc., and Spire Bioven-
tures Mintlabs. X. Montalban served on the scientific advisory board for
Bayer-Schering, Biogen-Idec, EMD Merck-Serono, Genentech, Gen-
zyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, and Almirall;
received travel funding from Novartis, Teva Pharmaceutical, EMD
Merck-Serono, Biogen-Idec, Bayer-Schering Pharma, Almirall, Genzyme,
and Sanofi-Aventis; is on the editorial board for Multiple Sclerosis Journal,
Journal of Neurology, The International MS Journal, Revista de Neurologia,
and Therapeutic Advances in Neurological Disorders; has consulted for
Bayer-Schering Pharma, Biogen-Idec, Genzyme, Merck, Novartis,
Sanofi-Aventis, and Teva Pharmaceutical; and received research support
from Multiple Sclerosis Foundation of Barcelona. F. Graus is on the
editorial board for Lancet Neurology, receives royalties from Euroimmun,
and holds a patent for use of IgLON5 as a diagnostic test. A. Saiz is on
the scientific advisory board for Biogen Idec and Merck Serono; received
travel funding and/or speaker honoraria from Bayer-Schering, Merck-
Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries,
and Novartis; and has consulted for Bayer-Schering, Merck Serono, Bio-
gen Idec, Sanofi-Aventis, Teva Pharmaceutical, and Novartis. Go to
Neurology.org/nn for full disclosure forms.
Received January 25, 2016. Accepted in final form February 24, 2016.
REFERENCES
1. Wingerchuk DM, Lennon VA, Pittock SJ,
Lucchinetti CF, Weinshenker BG. Revised diagnostic
criteria for neuromyelitis optica. Neurology 2006;66:
1485–1489.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF,
Pittock SJ, Weinshenker BG. The spectrum of neuromy-
elitis optica. Lancet Neurol 2007;6:805–815.
3. Wingerchuk DM, Banwell B, Bennett JL, et al. Interna-
tional consensus diagnostic criteria for neuromyelitis opti-
ca spectrum disorders. Neurology 2015;85:177–179.
4. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease
patterns in seropositive and seronegative neuromyelitis optica:
a multicentre study of 175 patients. J Neuroinflammation
2012;9:14.
5. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors
and disease course in aquaporin-4 antibody-positive pa-
tients with neuromyelitis optica spectrum disorder from
the United Kingdom and Japan. Brain 2012;135:
1834–1849.
6. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of
AQP4-IgG serostatus and disability outcome in neuromy-
elitis optica. Neurology 2013;81:1197–1204.
7. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction
between MOG antibody-positive and AQP4 antibody-
positive NMO spectrum disorders. Neurology 2014;82:
474–481.
8. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis
optica spectrum disorders with aquaporin-4 and myelin-
oligodendrocyte glycoprotein antibodies: a comparative
study. JAMA Neurol 2014;71:276–283.
9. Höftberger R, Sepulveda M, Armangue T, et al. Antibod-
ies to MOG and AQP4 in adults with neuromyelitis optica
and suspected limited forms of the disease. Mult Scler
2015;21:866–874.
10. Barkhof F, Filippi M, Miller D, et al. Comparison of
MRI criteria at first presentation to predict conversion
to clinically definite multiple sclerosis. Brain 1997;120:
2059–2069.
11. Höftberger R, Sabater L, Marignier R, et al. An optimized
immunohistochemistry technique improves NMO-IgG
detection: study comparison with cell-based assays. PLoS
One 2013;8:e79083.
12. Kurtzke JF. Rating neurologic impairment in multiple
sclerosis: an expanded disability status scale (EDSS). Neu-
rology 1983;33:1444–1452.
13. Nagaihi A, Takagi M, Umemura A, et al. Clinical features
of neuromyelitis optica in a large Japanese cohort: com-
parison between phenotypes. J Neurol Neurosurg Psychi-
atry 2011;82:1360–1364.
14. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG
serostatus and outcome in recurrent longitudinally
extensive transverse myelitis. JAMA Neurol 2014;71:
48–54.
8 Neurology: Neuroimmunology & Neuroinflammation
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
15. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquapor-
in-4 antibody-negative neuromyelitis optica: distinct assay
sensitivity-dependent entity. Neurology 2013;80:2194–2200.
16. Cobo-Calvo A, Sepúlveda M, Bernard-Valnet R, et al.
Antibodies to myelin oligodendrocyte glycoprotein in
aquaporin 4 antibody seronegative longitudinally extensive
transverse myelitis: clinical and prognostic implications.
Mult Scler 2016;22:312–319.
17. Di Pauli F, Höftberger R, Reindl M, et al. Fulminant
demyelinating encephalomyelitis: insights from antibody
studies and neuropathology. Neurol Neuroimmunol Neu-
roinflamm 2015;2:e175.
Neurology: Neuroimmunology & Neuroinflammation 9
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
